Key insights
- Stratasys announced new 3D printing tools and materials, including a lower-cost PolyJet printer and a biocompatible silicone for medical devices. Analysts forecast profitability for Stratasys in 2026. The news signals potential growth in the additive manufacturing sector, but the overall market impact on US equities is limited.
MINNETONOTA, Minn. & REHOVOT, Israel - Stratasys Ltd. (NASDAQ:SSYS) announced a range of new software capabilities, materials, and platform enhancements for additive manufacturing on Thursday.
The company introduced the J850 Core printer, a lower-cost PolyJet technology system designed for engineering teams focused on functional prototyping. The system supports rigid, flexible, transparent, and PolyJet ToughONE materials and is suited for producing enclosures, housings, jigs, and fixtures. The J850 Core is planned to be available for booking by the end of April.These product launches come as Stratasys works toward profitability, with the company posting a loss of $1.28 per share over the last twelve months. Yet analysts predict the company will be profitable this year, forecasting earnings of $0.12 per share for 2026. The company maintains a strong balance sheet with a current ratio of 3.57 and holds more cash than debt, according to InvestingPro data.
Stratasys and Shin-Etsu introduced P3 MED Silicone 25A, described as the first biocompatible true silicone for 3D printing patient-specific medical devices, available exclusively on Origin printers. The material is certified to ISO 10993 standards and enables production of devices including hearing aids, CPAP masks, orthotics, and prosthetics.
The company plans to launch an Additive App Suite later this summer with 10 apps, developed by software partner trinckle. The suite will be embedded into GrabCAD Print and GrabCAD Print Pro, with plans to expand to 15 apps by Formnext 2026 in November. The apps include automated design tools for industrial applications such as clamping jaws, shadow boards, and drill guides.
Stratasys also announced SAF PA12, powered by Evonik, which the company states offers up to 14% lower total cost of ownership compared to current SAF PA12 materials. The material delivers dimensionally accurate parts without requiring additional licenses, hardware, or process changes.
"Manufacturers are seeking more applications for additive manufacturing, and that’s exactly what these innovations are designed to provide," said Rich Garrity, President and Chief Business Unit Officer, according to a press release statement.
The products will be demonstrated at the RAPID + TCT Conference from April 14-16 at booth 1601.
In other recent news, Stratasys Ltd. reported its fourth-quarter 2025 earnings, showing consistent earnings per share (EPS) at $0.07, aligning with analyst forecasts. However, the company slightly missed revenue expectations, posting $140 million compared to the anticipated $142.56 million. In another development, Stratasys announced the expansion of its additive manufacturing portfolio with new materials and software, including the ULTEM 1010 filament for aerospace-grade parts. Additionally, the Stratasys Direct division was selected for the U.S. Department of Defense’s Joint Additive Manufacturing Acceptability IV Pilot Parts Program. This program is intended to accelerate the qualification and deployment of 3D-printed parts across military platforms. Furthermore, Stratasys’s TrueDent resins received CE marking as a Class IIa medical device in Europe, expanding their approved uses. Meanwhile, Craig-Hallum lowered its price target on Stratasys to $12 from $14, citing margin pressure and higher operating expenses. Despite these challenges, the firm maintained a Buy rating on the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.